JP7118073B2 - 抗ｔｉｍ－３抗体を用いてがんを処置する方法 - Google Patents

抗ｔｉｍ－３抗体を用いてがんを処置する方法 Download PDF

Info

Publication number
JP7118073B2
JP7118073B2 JP2019537099A JP2019537099A JP7118073B2 JP 7118073 B2 JP7118073 B2 JP 7118073B2 JP 2019537099 A JP2019537099 A JP 2019537099A JP 2019537099 A JP2019537099 A JP 2019537099A JP 7118073 B2 JP7118073 B2 JP 7118073B2
Authority
JP
Japan
Prior art keywords
cancer
tim
item
antibody
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503364A5 (enExample
JP2020503364A (ja
Inventor
ディミトリー ボビレフ，
アンドリュー アール． ファーガソン，
クリステン アン マッキーカーン，
ジン ワン，
Original Assignee
テサロ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テサロ， インコーポレイテッド filed Critical テサロ， インコーポレイテッド
Publication of JP2020503364A publication Critical patent/JP2020503364A/ja
Publication of JP2020503364A5 publication Critical patent/JP2020503364A5/ja
Priority to JP2022062862A priority Critical patent/JP7472190B2/ja
Application granted granted Critical
Publication of JP7118073B2 publication Critical patent/JP7118073B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019537099A 2017-01-09 2018-01-09 抗ｔｉｍ－３抗体を用いてがんを処置する方法 Active JP7118073B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022062862A JP7472190B2 (ja) 2017-01-09 2022-04-05 抗ｔｉｍ－３抗体を用いてがんを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762444354P 2017-01-09 2017-01-09
US62/444,354 2017-01-09
US201762582272P 2017-11-06 2017-11-06
US62/582,272 2017-11-06
PCT/US2018/013021 WO2018129553A1 (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-tim-3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022062862A Division JP7472190B2 (ja) 2017-01-09 2022-04-05 抗ｔｉｍ－３抗体を用いてがんを処置する方法

Publications (3)

Publication Number Publication Date
JP2020503364A JP2020503364A (ja) 2020-01-30
JP2020503364A5 JP2020503364A5 (enExample) 2021-02-18
JP7118073B2 true JP7118073B2 (ja) 2022-08-15

Family

ID=61163782

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537099A Active JP7118073B2 (ja) 2017-01-09 2018-01-09 抗ｔｉｍ－３抗体を用いてがんを処置する方法
JP2022062862A Active JP7472190B2 (ja) 2017-01-09 2022-04-05 抗ｔｉｍ－３抗体を用いてがんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022062862A Active JP7472190B2 (ja) 2017-01-09 2022-04-05 抗ｔｉｍ－３抗体を用いてがんを処置する方法

Country Status (14)

Country Link
US (2) US11926665B2 (enExample)
EP (1) EP3565594A1 (enExample)
JP (2) JP7118073B2 (enExample)
KR (1) KR102671283B1 (enExample)
CN (1) CN110382000A (enExample)
AU (1) AU2018205401B2 (enExample)
BR (1) BR112019014169A2 (enExample)
CA (1) CA3049536A1 (enExample)
IL (1) IL267803A (enExample)
MA (1) MA47206A (enExample)
MX (1) MX2019008208A (enExample)
SG (1) SG10201913083SA (enExample)
TW (2) TWI793094B (enExample)
WO (1) WO2018129553A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022087185A (ja) * 2017-01-09 2022-06-09 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171790A1 (es) 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
MX2019005116A (es) * 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
JP2019533458A (ja) * 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
EP3740506A1 (en) * 2018-01-16 2020-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CN113166071B (zh) 2018-10-03 2025-03-21 特沙诺有限公司 尼拉帕利盐
JP2022504228A (ja) 2018-10-03 2022-01-13 テサロ， インコーポレイテッド ニラパリブ遊離塩基の結晶形態
WO2020093023A1 (en) * 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
EP3897844B1 (en) 2018-12-19 2023-11-15 Deutsches Krebsforschungszentrum Pharmaceutical combination of anti ceacam6 and tim3 antibodies
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
AU2020207132A1 (en) * 2019-01-11 2021-06-24 Eli Lilly And Company TIM-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
AU2021256652A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
JP2023521227A (ja) 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN117120091A (zh) * 2021-04-13 2023-11-24 免疫医疗有限责任公司 靶向pd-1和tim-3的双特异性抗体
EP4326773A4 (en) 2021-04-23 2025-09-24 Suzhou Neologics Bioscience Co Ltd ANTIBODIES TARGETING TIM-3 AND THEIR USES
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
CN118043352A (zh) 2021-09-02 2024-05-14 德国癌症研究中心公共法律基金会 副作用减少的抗cecam6抗体
US20230391873A1 (en) * 2022-06-02 2023-12-07 Memorial Sloan-Kettering Cancer Center Methods for treating mismatch repair deficient locally advanced rectal cancer using dostarlimab
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
US20250034255A1 (en) * 2023-03-08 2025-01-30 Incyte Corporation Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2025014933A1 (en) * 2023-07-10 2025-01-16 Northwestern University Targeting tim-3 in mapk-driven glioma
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161270A1 (en) 2015-04-01 2016-10-06 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US20030229910A1 (en) 2002-04-17 2003-12-11 Richard Metz Short fragment homologous replacement to provide BSE resistant cattle
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US7824681B2 (en) 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
MY153248A (en) 2006-07-14 2015-01-29 Ac Immune Sa Humanized antibody against amyloid beta
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
KR101653548B1 (ko) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
SI3536710T1 (sl) 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
WO2013098420A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
WO2014165115A1 (en) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized anti-n2 antibodies
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
HUE045065T2 (hu) * 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
SI3215532T1 (sl) 2014-11-06 2020-02-28 F. Hoffmann-La Roche Ag Protitelesa proti TIM3 in postopki uporabe
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
US11203637B2 (en) 2016-08-26 2021-12-21 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
MX2019005116A (es) 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
WO2018129553A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
AR111651A1 (es) * 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161270A1 (en) 2015-04-01 2016-10-06 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Cancer, 2016, Vol.69, Suppl. 1, S102, Abstract No. 311

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022087185A (ja) * 2017-01-09 2022-06-09 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法
JP7472190B2 (ja) 2017-01-09 2024-04-22 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法

Also Published As

Publication number Publication date
WO2018129553A1 (en) 2018-07-12
TWI841209B (zh) 2024-05-01
MA47206A (fr) 2019-11-13
EP3565594A1 (en) 2019-11-13
BR112019014169A2 (pt) 2020-02-11
CN110382000A (zh) 2019-10-25
AU2018205401A1 (en) 2019-07-25
TW202319068A (zh) 2023-05-16
US20240301057A1 (en) 2024-09-12
TW201831196A (zh) 2018-09-01
AU2018205401B2 (en) 2025-01-02
TWI793094B (zh) 2023-02-21
CA3049536A1 (en) 2018-07-12
US11926665B2 (en) 2024-03-12
JP2020503364A (ja) 2020-01-30
IL267803A (en) 2019-09-26
JP7472190B2 (ja) 2024-04-22
US20190322746A1 (en) 2019-10-24
KR102671283B1 (ko) 2024-06-03
MX2019008208A (es) 2019-12-11
KR20190098263A (ko) 2019-08-21
JP2022087185A (ja) 2022-06-09
SG10201913083SA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
JP7472190B2 (ja) 抗ｔｉｍ－３抗体を用いてがんを処置する方法
US12415855B2 (en) Methods of treating cancer with anti-PD-1 antibodies
EA050059B1 (ru) Способы лечения рака с помощью антител к tim-3
EA043391B1 (ru) Способы лечения рака с помощью антител к pd-1
HK40016035B (en) Methods of treating cancer with anti-pd-1 antibodies
HK40016035A (en) Methods of treating cancer with anti-pd-1 antibodies
NZ795702A (en) Methods of treating cancer with anti-pd-1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220802

R150 Certificate of patent or registration of utility model

Ref document number: 7118073

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250